Antibody Responses to SARS-CoV-2 in Children With COVID-19
© The Author(s) 2022. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: The immunologic features of children with coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are not clearly delineated. This study was conducted to evaluate SARS-CoV-2-specific antibody responses in children with COVID-19.
METHODS: The levels of anti-spike (S) IgG, anti-SARS-CoV-2 IgG, and neutralizing antibody (NAb) were measured during various time points in children <19 years of age with COVID-19 in South Korea from February 2020 to September 2020.
RESULTS: One hundred sixty-five blood samples from 114 children with COVID-19 (43.9% asymptomatic and 56.1% mildly symptomatic) were analyzed. In both asymptomatic and mildly symptomatic children, the positive rates of anti-S IgG, anti-SARS-CoV-2 IgG, and NAb were low within 7 days after onset, but they soon reached 100% 14 to <28 days after onset. In symptomatic children, the geometric mean titers (GMTs) of antibodies were all below the positive cutoff during the first 2 weeks from onset and peaked at 28 to <56 days (5.6 for anti-S IgG, 383.6 for anti-SARS-CoV-2 IgG, and 55.0 for NAb, P < .001, respectively). Antibody levels remained detectable up to 3 months after infection. The antibody GMTs during the period 14 to <56 days after symptom onset were highest in children aged 0-4 years.
CONCLUSIONS: These results collectively present the humoral immune responses during SARS-CoV-2 infection in children. A further longitudinal study is needed to thoroughly understand the immune system and for effective vaccine development in children during the COVID-19 pandemic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of the Pediatric Infectious Diseases Society - 11(2022), 6 vom: 22. Juni, Seite 267-273 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Han, Mi Seon [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 24.06.2022 Date Revised 24.06.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/jpids/piac012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33806026X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33806026X | ||
| 003 | DE-627 | ||
| 005 | 20231225235822.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jpids/piac012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1126.xml |
| 035 | |a (DE-627)NLM33806026X | ||
| 035 | |a (NLM)35275210 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Han, Mi Seon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antibody Responses to SARS-CoV-2 in Children With COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.06.2022 | ||
| 500 | |a Date Revised 24.06.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: The immunologic features of children with coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are not clearly delineated. This study was conducted to evaluate SARS-CoV-2-specific antibody responses in children with COVID-19 | ||
| 520 | |a METHODS: The levels of anti-spike (S) IgG, anti-SARS-CoV-2 IgG, and neutralizing antibody (NAb) were measured during various time points in children <19 years of age with COVID-19 in South Korea from February 2020 to September 2020 | ||
| 520 | |a RESULTS: One hundred sixty-five blood samples from 114 children with COVID-19 (43.9% asymptomatic and 56.1% mildly symptomatic) were analyzed. In both asymptomatic and mildly symptomatic children, the positive rates of anti-S IgG, anti-SARS-CoV-2 IgG, and NAb were low within 7 days after onset, but they soon reached 100% 14 to <28 days after onset. In symptomatic children, the geometric mean titers (GMTs) of antibodies were all below the positive cutoff during the first 2 weeks from onset and peaked at 28 to <56 days (5.6 for anti-S IgG, 383.6 for anti-SARS-CoV-2 IgG, and 55.0 for NAb, P < .001, respectively). Antibody levels remained detectable up to 3 months after infection. The antibody GMTs during the period 14 to <56 days after symptom onset were highest in children aged 0-4 years | ||
| 520 | |a CONCLUSIONS: These results collectively present the humoral immune responses during SARS-CoV-2 infection in children. A further longitudinal study is needed to thoroughly understand the immune system and for effective vaccine development in children during the COVID-19 pandemic | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibody response | |
| 650 | 4 | |a children | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Um, Jihye |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Eun Joo |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Kyung Min |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Sung Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Hyunju |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Ye Kyung |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Youn Young |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Eun Young |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Dong Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Jae Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jina |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Misuk |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Ki-Hyun |e verfasserin |4 aut | |
| 700 | 1 | |a Min, Hye Sook |e verfasserin |4 aut | |
| 700 | 1 | |a Choe, Young June |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Dong-Gyun |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Jun-Sun |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Eun Hwa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the Pediatric Infectious Diseases Society |d 2012 |g 11(2022), 6 vom: 22. Juni, Seite 267-273 |w (DE-627)NLM227436326 |x 2048-7207 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:6 |g day:22 |g month:06 |g pages:267-273 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jpids/piac012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 6 |b 22 |c 06 |h 267-273 | ||